South Plainfield, NJ-February 26, 2019 – Today, MedCDx and Admera Health announced a non-exclusive collaborative agreement. Under the terms of the agreement, MedCDx (formerly Qiagen Suzhou Translational Medicine) and Admera Health will gain access to each other’s existing portfolios and co-develop new technologies, specifically companion diagnostics.
MedCDx has an expansive portfolio of molecular diagnostic capabilities, including manufacturing and services. These offerings include genomics, proteomics, cytology, and pathology solutions. Admera Health is a reference laboratory specializing in next-generation molecular diagnostics, specifically providing laboratory developed tests for pharmacogenomics, tumor profiling, and inherited cardiovascular testing. In addition, Admera Health also provides genomics and bioinformatics services to customers wishing to conduct research in a CLIA environment.
“By combining the expansive molecular diagnostics capabilities of MedCDx with Admera Health’s specialization in genomics and bioinformatics, we hope to develop and provide the next wave of molecular-based companion diagnostic innovations and services,” stated Guanghui Hu, Ph.D., President, and CEO of Admera Health. Hu continued, “In addition, given the geographic strengths of our respective companies, there will also be opportunities to expand clinical trials using each other’s proprietary technology in both China and the United States.”
Additional terms of the agreement between MedCDx and Admera Health were not disclosed.
MedCDx was established in 2013 with QIAGEN GmbH Germany as an industry-leading comprehensive translational medicine platform for nucleic acids, proteins, pathology and cell biology, and an experienced and highly qualified professional technical team. MedCDx provides biomarkers, verification, and new drug clinical solutions for molecular and in-situ screening for patient stratification, and development of test methods. Development and commercialization of accompanying diagnostic kits are pioneering innovators and leaders in the overall solution for precision diagnostics.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next-generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized medically actionable results.
Admera Health Contact: